IL270685A - - Google Patents
Info
- Publication number
- IL270685A IL270685A IL27068519A IL27068519A IL270685A IL 270685 A IL270685 A IL 270685A IL 27068519 A IL27068519 A IL 27068519A IL 27068519 A IL27068519 A IL 27068519A IL 270685 A IL270685 A IL 270685A
- Authority
- IL
- Israel
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
- C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762509378P | 2017-05-22 | 2017-05-22 | |
| US201762518280P | 2017-06-12 | 2017-06-12 | |
| US201762560413P | 2017-09-19 | 2017-09-19 | |
| PCT/US2018/033963 WO2018217808A1 (en) | 2017-05-22 | 2018-05-22 | Lipo-glycopeptide cleavable derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL270685A true IL270685A (https=) | 2019-12-31 |
| IL270685B IL270685B (en) | 2022-09-01 |
Family
ID=64395938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL270685A IL270685B (en) | 2017-05-22 | 2018-05-22 | Cleavable derivatives of lipoglycopeptide and their uses |
| IL270686A IL270686B (en) | 2017-05-22 | 2018-05-22 | Derivatives of glycopeptides and their uses |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL270686A IL270686B (en) | 2017-05-22 | 2018-05-22 | Derivatives of glycopeptides and their uses |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11071769B2 (https=) |
| EP (2) | EP3634464A4 (https=) |
| JP (2) | JP7165146B2 (https=) |
| KR (2) | KR102661786B1 (https=) |
| CN (2) | CN110996984A (https=) |
| AU (2) | AU2018271873B2 (https=) |
| BR (2) | BR112019024472A2 (https=) |
| GB (2) | GB2577419B (https=) |
| IL (2) | IL270685B (https=) |
| NZ (1) | NZ758836A (https=) |
| WO (2) | WO2018217808A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5548121B2 (ja) | 2007-05-14 | 2014-07-16 | リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク | バイオフィルム中の細菌細胞における生理学的分散応答の誘導 |
| IL270685B (en) | 2017-05-22 | 2022-09-01 | Insmed Inc | Cleavable derivatives of lipoglycopeptide and their uses |
| NL2023883B1 (en) * | 2019-09-24 | 2021-04-26 | Univ Leiden | Antibiotic compounds |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| WO2023094994A1 (en) * | 2021-11-24 | 2023-06-01 | Cumberland Pharmaceuticals Inc | Methods for the prevention or treatment of anthrax infection |
| CN121270649A (zh) * | 2024-07-03 | 2026-01-06 | 烟台新药创制山东省实验室 | 一类万古霉素衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4639433A (en) | 1985-08-14 | 1987-01-27 | Eli Lilly And Company | Glycopeptide derivatives |
| PT86457B (pt) * | 1986-12-30 | 1990-11-20 | Smithkline Beecham Corp | Processo para a preparacao de glicopeptidos glicosilados e de composicoes que os contem |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| PT101450B (pt) | 1994-02-02 | 1999-11-30 | Hovione Produtos Farmaceuticos | Novo dispositivo para inalacao |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| AU5719798A (en) | 1996-12-31 | 1998-07-31 | Inhale Therapeutic Systems, Inc. | Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
| WO1999016420A1 (en) | 1997-09-29 | 1999-04-08 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in nebulizers |
| AU756693B2 (en) | 1997-09-29 | 2003-01-23 | Novartis Ag | Stabilized bioactive preparations and methods of use |
| US6518242B1 (en) * | 1998-02-20 | 2003-02-11 | Theravance, Inc. | Derivatives of glycopeptide antibacterial agents |
| US6288234B1 (en) * | 1998-06-08 | 2001-09-11 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| UA73924C2 (en) | 1998-10-09 | 2005-10-17 | Nektar Therapeutics | Device for delivering active agent formulation to lungs of human patient |
| PT1140993E (pt) | 1998-12-23 | 2003-10-31 | Theravance Inc | Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos |
| MXPA01012246A (es) | 1999-05-28 | 2002-08-12 | Inhale Therapeutic Syst | Aparato y metodo para distribuir una cantidad medida de medicamento en aerosol. |
| US6606992B1 (en) | 1999-06-30 | 2003-08-19 | Nektar Therapeutics | Systems and methods for aerosolizing pharmaceutical formulations |
| US6586008B1 (en) | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| AU2001238020A1 (en) | 2000-02-04 | 2001-08-14 | Advanced Medicine, Inc. | Glycopeptide derivatives having antibiotic activity |
| CA2399640A1 (en) | 2000-02-11 | 2001-08-16 | Eli Lilly And Company | Selective n-acylation of a82846 glycopeptide analogs |
| PT1280520E (pt) | 2000-05-10 | 2014-12-16 | Novartis Ag | Pós à base de fosfolípidos para administração de fármacos |
| UA75083C2 (uk) * | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| TWI312785B (en) * | 2001-08-24 | 2009-08-01 | Theravance Inc | Process for preparing vancomycin derivatives |
| WO2004044222A2 (en) | 2002-11-12 | 2004-05-27 | Enzon Pharmaceuticals, Inc. | Polymeric prodrugs of vancomycin |
| JP2006528704A (ja) * | 2003-05-27 | 2006-12-21 | セラヴァンス インコーポレーテッド | グリコペプチド抗細菌剤と組み合わせたポリエンマクロライド抗真菌剤の使用 |
| TWI342312B (en) * | 2003-10-22 | 2011-05-21 | Theravance Inc | Hydrochloride salts of a glycopeptide phosphonate derivative |
| US20070185015A1 (en) * | 2005-02-28 | 2007-08-09 | Chiron Corporation and North China Pharmaceutical Corporation | Semi-synthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity |
| US7632918B2 (en) * | 2005-02-28 | 2009-12-15 | Novartis Vaccines And Diagnostics, Inc. | Semi-synthetic glycopeptides with antibiotic activity |
| MX2010003263A (es) | 2007-09-25 | 2010-06-02 | Novartis Ag | Tratamiento de trastornos pulmonares con medicamentos aerosolizados tales como vancomicina. |
| JP5855829B2 (ja) * | 2007-10-23 | 2016-02-09 | インスメッド， インコーポレイテッド | リポソーム化バンコマイシン製剤 |
| CA2710602A1 (en) * | 2007-12-26 | 2009-07-09 | Lead Therapeutics, Inc. | Novel semi-synthetic glycopeptides as antibacterial agents |
| WO2010048340A2 (en) * | 2008-10-24 | 2010-04-29 | Lead Therapeutics, Inc. | Novel semi-synthetic glycopeptides as antibacterial agents |
| GB2465863A (en) * | 2008-12-05 | 2010-06-09 | Lead Therapeutics Inc | Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections |
| US20120058198A1 (en) * | 2009-03-26 | 2012-03-08 | Pulmatrix, Inc. | Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis |
| US9682061B2 (en) * | 2009-04-28 | 2017-06-20 | The Medicines Company | Methods of treating bacterial infections using oritavancin |
| US9572774B2 (en) * | 2011-05-19 | 2017-02-21 | Savara Inc. | Dry powder vancomycin compositions and associated methods |
| JP6012716B2 (ja) | 2011-05-19 | 2016-10-25 | サヴァラ，インク． | 乾燥粉末バンコマイシン組成物および関連する方法 |
| WO2013022763A1 (en) | 2011-08-05 | 2013-02-14 | The Scripps Research Institute | Glycopeptide antibiotic analogs effective against vancomycin-resistant bacterial strains |
| PL2852391T3 (pl) * | 2012-05-21 | 2022-04-11 | Insmed Incorporated | Układy do leczenia infekcji płuc |
| US10124066B2 (en) * | 2012-11-29 | 2018-11-13 | Insmed Incorporated | Stabilized vancomycin formulations |
| GB201402267D0 (en) * | 2014-02-10 | 2014-03-26 | Cambridge Entpr Ltd | Antibacterial agents |
| CN105085636B (zh) * | 2014-05-19 | 2020-05-01 | 中国医学科学院药物研究所 | 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用 |
| CA2954653C (en) | 2014-07-10 | 2023-01-24 | The Scripps Research Institute | N-(hydrophobe-substituted)vancosaminyl [.psi.[c(=nh)nh]tpg4]vancomycin and [.psi.[ch2nh]tpg4]vancomycin |
| CN107325159A (zh) | 2016-04-29 | 2017-11-07 | 中国科学院上海药物研究所 | 一类万古霉素衍生物、其制备方法、药物组合物和用途 |
| WO2018008197A1 (ja) | 2016-07-07 | 2018-01-11 | 日東電工株式会社 | 反射層および蛍光体層付光半導体素子 |
| AU2017348434B2 (en) | 2016-10-31 | 2021-10-07 | The Scripps Research Institute | Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability |
| IL270685B (en) * | 2017-05-22 | 2022-09-01 | Insmed Inc | Cleavable derivatives of lipoglycopeptide and their uses |
-
2018
- 2018-05-22 IL IL270685A patent/IL270685B/en unknown
- 2018-05-22 BR BR112019024472-7A patent/BR112019024472A2/pt not_active Application Discontinuation
- 2018-05-22 CN CN201880048300.3A patent/CN110996984A/zh active Pending
- 2018-05-22 AU AU2018271873A patent/AU2018271873B2/en active Active
- 2018-05-22 EP EP18805177.5A patent/EP3634464A4/en active Pending
- 2018-05-22 GB GB1917675.9A patent/GB2577419B/en active Active
- 2018-05-22 IL IL270686A patent/IL270686B/en unknown
- 2018-05-22 KR KR1020197035481A patent/KR102661786B1/ko active Active
- 2018-05-22 EP EP18805750.9A patent/EP3630154A4/en active Pending
- 2018-05-22 WO PCT/US2018/033963 patent/WO2018217808A1/en not_active Ceased
- 2018-05-22 NZ NZ758836A patent/NZ758836A/en unknown
- 2018-05-22 KR KR1020197035485A patent/KR102661790B1/ko active Active
- 2018-05-22 US US16/615,214 patent/US11071769B2/en not_active Expired - Fee Related
- 2018-05-22 US US16/615,232 patent/US20200368312A1/en not_active Abandoned
- 2018-05-22 JP JP2019565425A patent/JP7165146B2/ja active Active
- 2018-05-22 WO PCT/US2018/033953 patent/WO2018217800A1/en not_active Ceased
- 2018-05-22 CN CN201880047233.3A patent/CN110891590B/zh active Active
- 2018-05-22 BR BR112019024549A patent/BR112019024549A2/pt not_active Application Discontinuation
- 2018-05-22 JP JP2019565468A patent/JP7210476B2/ja active Active
- 2018-05-22 GB GB1917677.5A patent/GB2577420B/en active Active
- 2018-05-22 AU AU2018273887A patent/AU2018273887B2/en active Active
-
2021
- 2021-06-10 US US17/344,322 patent/US11857597B2/en active Active